GILDHealthcare · Drug Manufacturers - GeneralThe 27 Wall Street analysts covering Gilead Sciences, Inc. hold a median 12-month price target of $164 — +13.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Gilead Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (50): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GILD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +13.4% from it.
Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HSBC | Maintains | Buy | $155 → $175 |
| 5 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 5 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 5 Aug 2026 | Needham | Reiterates | Buy | $170 |
| 5 Aug 2026 | Needham | Reiterates | Buy | — |
| 5 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 5 Aug 2026 | RBC Capital | Maintains | Sector Perform | $120 → $123 |
| 29 July 2026 | Barclays | Maintains | Equal-Weight | $155 → $145 |
| 29 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | $166 → $165 |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 21 July 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 21 July 2026 | Leerink Partners | Downgrade | Market Perform | $146 → $127 |
| 8 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 8 July 2026 | Morgan Stanley | Maintains | Overweight | $168 → $166 |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | $122 → $120 |
| 7 July 2026 | Truist Securities | Maintains | Buy | — |
| 7 July 2026 | Truist Securities | Maintains | Buy | $157 → $156 |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GILD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Gilead Sciences, Inc. returned +30.1% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 40% of US stocks
Cheaper than 21% of US stocks
Cheaper than 6% of US stocks
Cheaper than 25% of US stocks
Higher than 52% of US stocks
Higher than 48% of US stocks
Higher than 90% of US stocks
Higher than 89% of US stocks
Higher than 19% of US stocks
Higher than 31% of US stocks
Higher than 96% of US stocks
Higher than 80% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Gilead Sciences, Inc. has a market value of $179.5B and an enterprise value of $200.8B.
Revenue in the twelve months to 30 June 2026: $30.5B. The latest quarter grew 10.2% year on year.
Net income over the same four quarters: −$3.2B, a −10.6% net margin.
Diluted earnings per share, trailing twelve months: $−2.67.
Free cash flow in the twelve months to 30 June 2026: $12.9B.
Gilead Sciences, Inc. spent $1.4B on share buybacks and $4.1B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 17.9×; forward P/E: 14.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.27%, paying out 43% of earnings.
Gilead Sciences, Inc. employs 17,000 people — $1.8M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Gilead Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Gilead Sciences (GILD) shares closed at $144.74 in the most recent trading session, down 1.87% from the prior session, even as the broader market gained.
Why it matters — A GILD watcher would care because the stock underperformed the market on the day, showing a decline while the overall market moved higher.
Barron's notes that Gilead shares have risen 35% since the publication first highlighted them, but its identified catalysts have not yet fully materialized. The article suggests more upside remains for the stock.
Why it matters — Gilead watchers would note that a prominent financial publication still sees additional upside potential and believes key catalysts have yet to fully play out.
Gilead Sciences (GILD) has been among the most-watched stocks on Zacks.com recently, according to the site. Zacks notes that it is worth exploring what may lie ahead for the stock.
Why it matters — The item signals that GILD has drawn notable attention from investors on Zacks, prompting a look at its near-term prospects.
Gilead Sciences (GILD) shares declined 1.21% in the latest trading session, closing at $149.45, a drop larger than the broader market's move. Zacks flagged the slide as information for investors.
Why it matters — GILD watchers would care because the stock underperformed the market in recent trading, signaling a notable single-day price movement for the company.
The item highlights a genetic discovery with potential implications for future Alzheimer's research and treatments. It also notes an experimental Gilead therapy showing promise against a difficult-to-treat form of blood cancer, and a new method for studying cells linked to age-related disorders.
Why it matters — A GILD watcher would care because the item reports on an experimental Gilead therapy showing promise against a difficult-to-treat blood cancer, signaling potential progress in the company's oncology pipeline.
The 27 Wall Street analysts covering Gilead Sciences, Inc. have a median 12-month price target of $164, with estimates ranging from $123 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering Gilead Sciences, Inc., 21 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gilead Sciences, Inc. 94 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Gilead Sciences, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +13.4% from the last close, and Ticker Nerd's factor model ranks Gilead Sciences, Inc. 94 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Gilead Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GILD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $123 to $180 over the next 12 months.
Gilead Sciences, Inc. returned +30.1% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases with unmet medical needs.
The most recent item we track (Zacks Investment Research, 2 Oct 2026): "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know". Gilead Sciences (GILD) shares closed at $144.74 in the most recent trading session, down 1.87% from the prior session, even as the broader market gained.
Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases with unmet medical needs. Gilead Sciences specializes in therapeutic areas including HIV, viral hepatitis, oncology, inflammation, respiratory conditions, and cardiovascular disease. Its current portfolio includes prescription medicines and specialty treatments used in hospitals, clinics, and long-term care settings, supporting patients across global markets. The company also maintains an active pipeline in virology, oncology, and inflammation, reinforcing its role as a major provider of branded therapies in modern healthcare. Headquartered in Foster City, California, Gilead Sciences serves physicians, healthcare systems, and patients through a diversified product portfolio centered on infectious disease and specialty care.
CEO Mr. Daniel Patrick O'Day · 17,000 employees · United States · https://www.gilead.com
